Gefitinib in lung cancer therapy: clinical results, predictive markers of response and future perspectives.
Over the past few years, epidermal growth factor receptor has emerged as one of the most important targets in tumorgenesis and several drugs targeting signal transduction pathways have been developed. The first among these agents to be approved for the treatment of NSCLC was gefitinib, a potent, selective and reversible inhibitor of HER1/EGFR tyrosine kinase activity. The review summarizes its clinical development and the new therapeutic options, with particular focus on predictive markers of susceptibility to this drug.
Adamo
Vincenzo
V
Department of Human Pathology, Medical Oncology and Integrated Therapies Unit, University Policlinic G. Martino of Messina, Messina, Italy. vadamo@unime.it
Franchina
Tindara
T
Adamo
Barbara
B
Denaro
Nerina
N
Gambadauro
Pietro
P
Chiofalo
Giuseppe
G
Scimone
Antonino
A
Caristi
Nicola
N
Russo
Antonio
A
Giordano
Antonio
A
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015415:Biomarkers; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002986:Clinical Trials as Topic / Q000639:trends; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D011799:Quinazolines / Q000627:therapeutic use*; D015398:Signal Transduction / Q000187:drug effects
D000970:Antineoplastic Agents; D015415:Biomarkers; D011799:Quinazolines; C512478:EGFR protein, human; D066246:ErbB Receptors; D000077156:Gefitinib